Incidence, risk factors and outcomes of sclerosis in patients with chronic graft-versus-host disease.

Publication Type:

Journal Article


Blood, Volume 121, Issue 25, p.5098-103 (2013)


2013, April 2013, Center-Authored Paper, Clinical Research Division, Collaborative Data Services Core Facility, Public Health Sciences Division, Research Trials Office Core Facility - Biostatistics Service


Key points Incidence of sclerotic graft-versus-host disease (GVHD) is 20% by 3 years after initial systemic treatment of chronic GVHD.The use of mobilized blood cell graft and total body irradiation conditioning are associated with an increased risk of sclerotic GVHD.